Mark Hollywood Biography and Net Worth

COO of Zymeworks

Mr. Hollywood joined Zymeworks in 2019 and currently serves as our Executive Vice President and Chief Operating Officer. Mr. Hollywood brings over 25 years of experience in the biopharmaceutical industry, most recently as Vice President and Head of ZymoGenetics (a Bristol-Myers Squibb company), where he oversaw biologics development, manufacturing, quality, and supply chain operations. He joined ZymoGenetics in 2010 and led technical operations for a portfolio of clinical and commercial products, and was responsible for building and managing a multi-host drug substance manufacturing facility. Mr. Hollywood brings a wealth of experience in operations management, having held positions of increasing responsibility in process science, manufacturing, quality, and regulatory compliance at organizations including Amgen, Dendreon and Centeon (a Rhone-Poulenc Rorer and Hoescht company). Mr. Hollywood has a Bachelor of Science degree in Biological Sciences from Western Illinois University.

What is Mark Hollywood's net worth?: The estimated net worth of Mark Hollywood is at least $2.99 million as of January 12th, 2026. Hollywood owns 132,913 shares of Zymeworks stock worth more than $2,994,530 as of February 1st. This net worth estimate does not reflect any other assets that Hollywood may own. Learn More about Mark Hollywood's net worth.
How old is Mark Hollywood?: Hollywood is currently 54 years old. There are 3 older executives and no younger executives at Zymeworks. The oldest executive at Zymeworks is Ms. Leone D. Patterson M.B.A., CFO, EVP & Chief Business Officer, who is 62 years old. Learn More on Mark Hollywood's age.
How do I contact Mark Hollywood?: The corporate mailing address for Hollywood and other Zymeworks executives is 1385 WEST 8TH AVENUE SUITE 540, VANCOUVER A1, V6H 3V9. Zymeworks can also be reached via phone at (302) 274-8744 and via email at [email protected]. Learn More on Mark Hollywood's contact information.
Has Mark Hollywood been buying or selling shares of Zymeworks?: During the last quarter, Mark Hollywood has sold $138,740.40 in shares of Zymeworks stock. Most recently, Mark Hollywood sold 6,120 shares of the business's stock in a transaction on Monday, January 12th. The shares were sold at an average price of $22.67, for a transaction totalling $138,740.40. Following the completion of the sale, the chief operating officer now directly owns 132,913 shares of the company's stock, valued at $3,013,137.71. Learn More on Mark Hollywood's trading history.
Who are Zymeworks' active insiders?: Zymeworks' insider roster includes Kenneth Galbraith (Chair & CEO), Mark Hollywood (COO), Neil Josephson (Insider), Neil Klompas (CFO), Paul Moore (Chief Scientific Officer), Kathryn O'Driscoll (Insider), James Priour (Insider), Jeffrey Smith (Executive Vice President and Chief Medical Officer), and Ali Tehrani (CEO). Learn More on Zymeworks' active insiders.
Are insiders buying or selling shares of Zymeworks?: During the last twelve months, Zymeworks insiders bought shares 13 times. They purchased a total of 1,405,768 shares worth more than $16,773,032.28. During the last twelve months, insiders at the sold shares 8 times. They sold a total of 187,933 shares worth more than $4,673,716.04. The most recent insider tranaction occured on January, 12th when CEO Kenneth Galbraith sold 30,424 shares worth more than $689,712.08. Insiders at Zymeworks own 33.5% of the company. Learn More about insider trades at Zymeworks.
Information on this page was last updated on 1/12/2026.

Mark Hollywood Insider Trading History at Zymeworks

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
1/12/2026	Sell	6,120	$22.67	$138,740.40	132,913

Mark Hollywood Buying and Selling Activity at Zymeworks

Zymeworks Company Overview

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. It also develops a pipeline of preclinical product candidates and discovery-stage programs in oncology, including immuno-oncology agents and other therapeutic areas. Zymeworks Inc. has strategic partnerships and collaborations with BeiGene, Ltd.; Celgene Corporation; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; LEO Pharma A/S; Iconic Therapeutics, Inc.; Merck Sharp & Dohme Research GmbH; and Atreca, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Today's Range

Now: $22.53

$22.00

$22.77

50 Day Range

MA: $25.22

$22.31

$27.62

2 Week Range

Now: $22.53

$9.03

$28.49

Volume

560,163 shs

Average Volume

970,858 shs

Market Capitalization

$1.69 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.3

Mark Hollywood Biography and Net Worth

What is Mark Hollywood's net worth?

How old is Mark Hollywood?

How do I contact Mark Hollywood?

Has Mark Hollywood been buying or selling shares of Zymeworks?

Who are Zymeworks' active insiders?

Are insiders buying or selling shares of Zymeworks?